We’ll Be Highlighting (Nasdaq: MDCX) Tomorrow Morning—Pull it Up Tonight

Any content you receive is for information purposes only. Always conduct your own research.  *Disseminated on Behalf of Medicus Pharma Ltd. Jeff Ackerman Just Put Medicus Pharma Ltd. (NASDAQ: MDCX) At The Top Of Tomorrow’s Watchlist—Wednesday, April 15, 2026 Don’t Miss The Next Breakout—Get Real-Time Alerts Sent Directly To Your Phone. Up To 10X Faster Than Email. Expect Full Coverage On (MDCX) To Start Early Get (MDCX) On Your Radar Before Tomorrow Morning… April 14, 2026 We’ll Be Highlighting (Nasdaq: MDCX) Tomorrow Morning | Pull it Up Tonight Dear Reader, For decades, the standard approach to treating basal cell carcinoma has often involved surgical removal—effective, but not without trade-offs, especially for patients dealing with multiple or recurring lesions. Now, early-stage clinical data is beginning to point toward a different possibility… one that uses a localized delivery method designed to target the lesion directly, without the need for traditional surgical intervention. In a recent Phase 2 study, this approach demonstrated clinical clearance in a meaningful percentage of patients at higher dose levels. That shift—from conventional procedures to precision-based delivery—is what brings us to Medicus Pharma Ltd. (NASDAQ: MDCX). And this is exactly why (MDCX) will be topping our watchlist tomorrow morning—Wednesday, April 15, 2026. But keep in mind, one analyst has a target on (MDCX) that you’ll want to see. Jason McCarthy, Ph.D., Senior Managing Director, Head of Biotechnology Research at Maxim Group, has a $6 target on (MDCX) which suggests 1,400% upside potential from its recent $.40 range. Headquartered in Philadelphia, Medicus Pharma Ltd. (NASDAQ: MDCX) operates with a distinct capital-efficient model designed to accelerate the clinical programs of disruptive therapeutic assets. Rather than bearing the massive costs of late-stage global commercialization, the company’s stated strategy is to advance select candidates through Phase 2 clinical proof-of-concept and subsequently pursue high-value licensing or strategic partnerships with established pharmaceutical firms. This model is currently being tested through two primary therapeutic pillars: the SkinJect™ platform for dermatology and oncology, and the Teverelix hormone-suppression program. Dermatology Pillar: SkinJect™ and the D-MNA Platform The company's lead asset, SkinJect™ (D-MNA), is a novel localized immuno-oncology precision product. It utilizes a patented dissolvable microneedle patch to deliver doxorubicin directly into basal cell carcinoma (BCC) lesions. This non-invasive delivery method aims to provide a viable alternative to surgical resection, which can often be disfiguring for patients with multiple or recurrent lesions. Phase 2 Milestones: In December 2025, Medicus successfully completed enrollment of 90 patients in its U.S.-based randomized, double-blind Phase 2 study (SKNJCT-003). Topline Data Validation: Topline results released in early 2026 revealed highly promising results, particularly in the highest dose (200ug) cohort, which showed up to a 73% clinical clearance rate. Surgical Avoidance: Key opinion leaders have highlighted that the data suggests approximately 3 out of 4 patients treated with the optimal dose may avoid immediate surgery. Regulatory Path: Following a Type C meeting with the FDA, the company is pursuing a potential 505(b)(2) regulatory pathway, which could significantly compress the time to market. Hormone-Suppression Pillar: Teverelix In August 2025, Medicus significantly expanded its portfolio by acquiring Antev, a UK-based biotech developing Teverelix. Teverelix is a next-generation long-acting GnRH antagonist designed to suppress sex hormone production without the initial "testosterone flare" associated with legacy GnRH agonists. Cardiovascular Safety: The mechanism of Teverelix is particularly beneficial for high-risk cardiovascular patients with advanced prostate cancer, as it reduces the physiological stress caused by hormonal surges. Recent FDA Clearance: In February 2026, the company received "study may proceed" clearance to initiate its Phase 2b dose-optimization study in men with advanced prostate cancer. Optimized Royalty Structure: To enhance the drug’s long-term economic profile, Medicus successfully reduced the royalty rate payable on worldwide net sales from approximately 4% down to 2%. The Agentic AI Strategy: Scaling Through Simulation A unique differentiator for Medicus is its integration of agentic AI-driven clinical development capabilities. In December 2025, the firm entered into a collaboration with Reliant AI Inc. to develop a platform optimized for: Protocol Simulation: Testing trial designs in a virtual environment before patient enrollment. Dynamic Site Selection: Identifying geographic locations with the highest concentration of target patient populations to accelerate enrollment. Patient Stratification: Utilizing pharmacodynamic-informed data to ensure the most responsive participants are prioritized, thereby de-risking the clinical outcome. Financial and Market Metrics Medicus enters the second quarter of 2026 with a market capitalization of approximately $16M and a cash position of $8.7M as of Q2 2026. During fiscal year 2025, the company successfully raised approximately $31.9M in total financing proceeds to fund its accelerated Phase 2 programs. While the company currently reports a net loss consistent with high-growth biotech development ($47.3M for FY2025), management emphasizes that their capital-efficient model is focused on near-term value creation through proof-of-concept readouts rather than a long-term cash-intensive commercial build-out. Recent Developments April 06, 2026 Medicus Pharma Submits Optimized Phase 2 Study Protocol to U.S. FDA for Teverelix in Acute Urinary Retention April 01, 2026 Medicus Pharma Ltd Clarifies Positive SkinJect Phase 2 Dataset March 30, 2026 Medicus Pharma Reports KOL Validation of SkinJect Phase 2 Data of 80% Overall Response Rate March 26, 2026 Medicus Pharma Business Update Call to Highlight 80% Overall Response Rate (ORR) in Phase 2 SkinJect Study and Agentic AI-enabled Drug Development Plan March 16, 2026 Medicus Pharma Announces SkinJect® Phase 2 Principal Investigator and Key Opinion Leader (KOL), Babar K. Rao MD, FAAD, to Provide Clinical Interpretation of Positive Data During Business Update Webcast on March 26 March 09, 2026 Medicus Pharma Provides Interpretation of Positive Phase 2 SkinJect™ Dataset March 05, 2026 Medicus Pharma Reports Positive Phase 2 SKNJCT-003 Topline Data Observing 73% Clinical Clearance and 40% Histological Clearance (CR) at Day 57 in 200µg Cohort March 03, 2026 Medicus Pharma To Participate in the 38th Annual Roth Conference February 10, 2026 Medicus Pharma Receives FDA "Study May Proceed" Clearance For Teverelix® Phase 2b Study in Advanced Prostate Cancer Patients with High Cardiovascular Risk 7 Reasons Why (MDCX) Will Be Topping Our Watchlist Tomorrow Morning—Wednesday, April 15, 2026… 1. Analyst Coverage: one biotechnology analyst has published a $6 target on (MDCX), which suggests 1,400% upside potential from its recent $.40 range. 2. Clinical Signal: recent Phase 2 data showed that (MDCX) achieved up to a 73% clinical clearance rate in higher dose cohorts, indicating measurable biological activity. 3. Non-Surgical Approach: a localized microneedle delivery system being developed by (MDCX) is designed to target lesions directly, offering a potential alternative to traditional surgical procedures. 4. Pipeline Expansion: the addition of Teverelix gives (MDCX) exposure to a second therapeutic area focused on hormone suppression without the initial flare seen in older approaches. 5. FDA Progress: a recent “study may proceed” clearance allows (MDCX) to move forward with a Phase 2b study in advanced prostate cancer patients. 6. Partnership Model: rather than building a full commercial infrastructure, (MDCX) is structured to advance programs through Phase 2 and pursue licensing or strategic partnerships. 7. AI Integration: a collaboration with Reliant AI positions (MDCX) to use simulation and data-driven tools to optimize trial design and patient selection. Pull Up (MDCX) Before Tomorrow Morning… When you step back and connect the dots, a clearer picture begins to form. A Phase 2 program showing up to 73% clinical clearance at higher doses… a non-surgical approach designed to target lesions directly… and a second program advancing with FDA clearance into Phase 2b. Layer in a capital-efficient structure built around advancing programs to proof-of-concept, along with a collaboration using AI to refine trial design and patient selection, and you begin to see how multiple pieces are moving at once. It’s also worth noting that one biotechnology analyst has placed a $6 target on (MDCX), which suggests 1,400% upside potential from its recent $.40 range. We will have all eyes on (MDCX) tomorrow morning. Take a look at (MDCX) before you call it a night. Jeff Ackerman Managing Editor Stock News Trends StockNewsTrends.com (“StockNewsTrends” or “SNT” ) is owned by TD Media LLC, a single member limited liability company. Data is provided from third-party sources and SNT is not responsible for its accuracy. Make sure to always do your own research and due diligence on any day and swing profile SNT brings to your attention. Any emojis used do not have a specific defined meaning, and may be used inconsistently. We do not provide personalized in-vest-ment advice, are not in-vest-ment advisors, and any profiles we mention are not suitable for all in-vest-ors. Pursuant to an agreement between TD Media LLC and Goldwyn Media LLC, TD Media LLC has been hired for a period beginning on 04/14/2026 and ending on 04/15/2026 to publicly disseminate information about (MDCX:US) via digital communications. Under this agreement, Goldwyn Media LLC has paid TD Media LLC one hundred thousand USD (“Funds”). To date, including under the previously described agreement, TD Media LLC has been paid one million forty thousand USD (“Funds”). These Funds were part of the one hundred thousand USD funds that TD Media LLC received from a third party named Goldwyn Media LLC who did receive the Funds directly or indirectly from the Issuer and does not own stock in the Issuer but the reader should assume that the clients of the third party own shares in the Issuer, which they will liquidate at or near the time you receive this communication and has the potential to hurt share prices. Neither TD Media LLC and their member own shares of (MDCX:US). Please see important disclosure information here: https://lifewatermedia.com/disclosure/mdcx-7E33I/#details

TD Media LLC | 5826 New Territory Blvd., Unit #2144, Sugar Land, TX 77479 Unsubscribe Update Profile | About our service provider Sent by jeff@stocknewstrends.com